Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety.

Mahlangu, Johnny; Levy, Howard; Kosinova, Marina V; Khachatryan, Heghine; Korczowski, Bartosz; Makhaldiani, Levani; Iosava, Genadi; Lee, Martin; Del Greco, Frank

Mahlangu, Johnny; Levy, Howard; Kosinova, Marina V; Khachatryan, Heghine; Korczowski, Bartosz; Makhaldiani, Levani; Iosava, Genadi; Lee, Martin; Del Greco, Frank.

Afiliación

Mahlangu J; Haemophilia Comprehensive Care Center Charlotte Maxeke Johannesburg Academic Hospital University of the Witwatersrand and NHLS Johannesburg South Africa.
Levy H; Catalyst Biosciences South San Francisco CA USA.
Kosinova MV; Hematology Kemerovo Regional Clinical Hospital Kemerovo Russia.
Khachatryan H; R.H. Yeolyan Hemophilia and Thrombophilia Center Yerevan Republic of Armenia.
Korczowski B; Institute of Medical Sciences College of Medical Sciences of the University of Rzeszow, University of Rzeszow Rzeszow Poland.
Makhaldiani L; K. Eristavi National Center of Experimental and Clinical Surgery Tbilisi Georgia.
Iosava G; Institute of Hematology and Transfusiology Tbilisi Georgia.
Lee M; Fielding School of Public Health University of California Los Angeles Los Angeles CA USA.
Del Greco F; Catalyst Biosciences South San Francisco CA USA.

Res Pract Thromb Haemost ; 5(6): e12576, 2021 Aug.

Article en En | MEDLINE | ID: mdl-34430790

Palabras clave

hemophilia; marzeptacog alfa (activated); prophylaxis; recombinant FVIIa; subcutaneous injection

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Res Pract Thromb Haemost Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google